| Name research group | Topic research group | Type of research |
|---|---|---|
| Breast Cancer Research Group (PI Prof Valentina Guarneri) | The Breast Cancer Research Group focuses on the biological and clinical characterization of breast cancer across all disease stages, integrating clinical research, translational analyses and artificial intelligence approaches to advance precision oncology. Main research areas include biomarker discovery and validation, treatment personalization and optimization (including biomarker-driven treatment de-/escalation), and the molecular dissection of tumor evolution and resistance mechanisms from early to metastatic disease. The group leverages multi-omic and liquid biopsy analyses, as well as AI-based data integration, to uncover hidden biological and clinical patterns. The group collaborates nationally and internationally with leading academic centers and consortia to foster innovation and accelerate translation from bench to bedside. | Clinical trials (profit and non-profit); investigator-initiated academic studies; translational and biomarker-driven projects; AI-based integrative analyses; observational and real-world data studies. |
| Gastrointestinal Research Group (Oncology 1 and 3) – P.I. Dr Sara Lonardi, Dr Francesca Bergamo | The research group is focused on biomarkers and precision treatment strategies for gastrointestinal cancers, including colorectal, esophageal and gastric, pancreatic, hepatobiliary, GEP-NET and rare GI tumors. Activities include: clinical trials with innovative agents, translational studies on prognostic and predictive biomarkers, the integration of ctDNA and molecular profiling into clinical practice, radiomic projects. Key areas: -Biomarker-driven treatment selection in GI cancers – ctDNA for prognostic and predictive applications in colorectal, pancreatic and gastric cancer – research and registries in rare GI cancers and hereditary syndromes – multidisciplinary and multimodal projects, including: mainstreaming pathways for Lynch syndrome detection, advanced surgical strategies and liver transplantation for selected colorectal and biliary tract cancers. The group collaborates in national and international research networks, supporting the advancements into personalized GI cancer care. | Clinical trials (no profit and profit); observational retrospective and prospective studies; translational studies; data collection within registry studies for rare tumors |
| HPV cancerogenesis Research Group (PI Dr Annarosa Del Mistro) | The research group is involved in national and regional studies aimed at investigating HPV-related cervical and oropharyngeal lesions. Both prevention and management of these lesions can be improved by implementing a risk-based and personalised approach. Several cellular (i.e., methylation status, expression of HPV-induced proteins) and viral (I.e., HPV genotyping, methylation) biomarkers are under investigation. Their role is evaluated in primary cervical screening and in the management of HPV-associated lesions (i.e., for prediction of lesion regression), comparing their performance as standalone biomarker or as biomarkers’ combinations. | Translational research No-profit clinical trials |
| Melanoma predisposition (PI Dr Chiara Menin) | Principal scientific interests are the genetic risk factors for cutaneous melanoma. Rare high-penetrance and common medium/low-penetrance factors are researched and assessed in the context of familial cancer history and the presence of non-genetic risk factors. The major objective is to improve the knowledge of the genetic basis of familial melanoma, also within the wider framework of the melanoma cancer syndrome characterized by the presence of different tumors. A further research focus is the development and refinement of polygenic risk scores aimed at improving the stratification of individual genetic susceptibility to melanoma. | Translational research |
| Targeted therapies in lymphoid malignancies through proteomic/metabolomic approaches (PI Dr Erich Piovan) | Our research aims include: (i) determining the role branched chain amino acid (BCAA) metabolism in T-cell acute lymphoblastic leukemia (T-ALL) pathogenesis and other NOTCH-1 dependent tumours using cell lines, patient-derived xenograft (PDX) samples and murine models of NOTCH1-induced leukemia through metabolomic and gene expression studies; (ii) identify regulators of BCAT1 expression in leukemia; (iii) pursue new therapeutic avenues i.e. (a) characterize ferroptosis susceptibility in T-ALL subtypes; (b) identify key regulators of ferroptosis in T-ALL; (c) evaluate the therapeutic potential of ferroptosis induction. | Translational Research |
| Hereditary Breast and Ovarian Cancer Syndrome Group (PI Dr Marco Montagna, Dr Lidia Moserle) | The research group is involved in the study of genetic variants in breast, ovarian, prostate and pancreatic cancers. Primary aims of the different research lines are: a) to improve risk assessment in BRCA1 and BRCA2 carriers through modifier genes identification; b) to increase the number of families with an informative genetic test by the use of multi-gene panels and the multifactorial characterization of variants of unknown clinical significance; c) to implement genetic tests on DNA damage repair genes on tumor cells to detect somatic and germline alterations leading to targeted therapies; d) to translate the most recent scientific achievements into clinical-diagnostic pathways for genetic testing and clinical management of patients and healthy carriers. | Translational research |
| EMP and metastasis (PI Dr Maria Luisa Calabrò) | Our research activity is mainly focused on the study of the role of epithelial-mesenchymal plasticity (EMP) in the pathogenesis of highly aggressive tumors. EMP-related pathways are linked to tumor progression, stemness and chemoresistance, and characterization of these processes may lead to the identification of novel prognostic biomarkers and therapeutic targets. In the last years, in collaboration with Dr. Sommariva’s Advanced Surgical Oncology Unit and the Histology and Pathology Unit, we have been studying, in 2D and 3D models, the role of stemness-related factors in peritoneal spread and aggressiveness of rarer peritoneal metastases, i.e. pseudomyxoma peritonei and malignant peritoneal mesothelioma. | Translational research |
| Tumor molecular biomarkers and pharmacogenetics group (PI Dr Matteo Curtarello, Dr Elisa Boldrin) | 1) Molecular multi-omics analyses of genetic and epigenetic biomarkers, with prognostic and therapeutic potential, by using solid biopsy and different liquid biopsy biosources (i.e. cell-free DNA and platelets). 2) Pharmacogenetics analyses with the aim to improve clinical management of cancer patients, typically receiving a polytherapeutic regimen. These analyses allow to maximize drugs’ efficacy and minimize adverse drug reactions. This research field is carried out in collaboration with the “translational research group”, PI Coppola. | Translational research |
| Genito-urinary Oncology Research Group of the Oncology Units (Oncology 1 & Oncology 3) | Biomarkers and treatment selection for patients with prostate, urothelial and renal cancer; trial with new therapeutical agents; biomarker and familiarity in testicular cancer; data collection and therapy for rare GU cancers; ctDNAs role (predictive, prognostic) in prostate and urothelial cancer; mutated prostate cancers (BRCA pathway) | Clinical trial, no profit and profit; observational data collection; translational and lab research; academic studies |
| Gynecological Cancers Research Group (PI Prof ValentinaGuarneri) | The Gynecologic Oncology Research Group focuses on the clinical and translational investigation of ovarian, cervical and endometrial cancers, integrating molecular profiling, biomarker discovery, and precision medicine approaches. Major research areas include the management of ovarian cancer and mechanisms of sensitivity and resistance to PARP inhibitors. Additional research addresses the biological and clinical heterogeneity of endometrial cancer through molecular analyses and real-world data integration. The group is also involved in projects with national partners. | Clinical trials (profit and non-profit); investigator-initiated academic studies/translational projects. |
| Head and Neck Cancer Research Group (PI Dr Maria Grazia Ghi) | The Head and Neck Cancer Research Group focuses on the clinical and biological investigation of tumours of the head and neck region, including both early-stage and metastatic disease. In the case of locally advanced disease, particular attention is given to young patients with oral cavity carcinoma. The aim is to identify distinct clinical and biological features, including those related to the tumour microenvironment (TME), in order to define predictive and prognostic factors and improve risk stratification. In the metastatic setting, the group is engaged in clinical research into immunotherapy-based treatments, conducting prospective and retrospective real-world studies in collaboration with centres in Italy and Europe. The group is also deeply involved in studying rare head and neck tumours, with a particular focus on the molecular biology of salivary gland cancers. In collaboration with the Molecular Tumor Board of the Veneto Region, the group aims to identify personalised therapeutic approaches and expand current knowledge of very rare cancers. | Clinical trials (profit and non-profit); investigator-initiated studies/translational projects. |
| Neuro-Oncology Research Group – PI Dr Giuseppe Lombardi | Clinical and translational research in central nervous system tumors, including gliomas, meningiomas, ependymomas, and rare primary brain neoplasms. The group focuses on the development of innovative therapeutic strategies, biomarker discovery and validation (prognostic and predictive), radiogenomic and molecular profiling, and the integration of advanced imaging in clinical decision-making. The group actively participates in national and international collaborative studies within networks such as EORTC, AIOM, and EANO. | Clinical trials (profit and no-profit); investigator-initiated academic studies; translational and biomarker-driven projects; registry-based and real-world evidence analyses; collaborative multicenter research integrating clinical, imaging, and molecular data. |
| Melanoma, soft tissue sarcoma and peritoneal tumors group | 1) Cancer biomarkers with prognostic and therapeutic potential (with special regard to melanoma, sarcomas and peritoneal tumors). 2) Translational studies within the frame of clinical trials (with special regard to melanoma, sarcomas and peritoneal tumors). 3) Quality Assurance and cost-effectiveness of clinical pathways for melanoma and sarcomas care. 4) Observational studies in surgical oncology (with special regard to melanoma, sarcomas and peritoneal tumors) | Clinical trial, no profit and profit; observational data collection; translational and lab research; academic studies |
| Molecular Oncology (PI Prof Vincenzo Ciminale) | Our group investigates how drug resistance is linked to metabolic reprogramming in cancer cells. We focus on hematologic cancers that fail to respond to standard treatment, aiming to identify metabolic vulnerabilities that can be exploited through synthetic-lethality strategies. In pediatric T-lymphoblastic leukemia (T-ALL), we have obtained promising results with: (i) the G6PD inhibitor dehydroepiandrosterone (Silic-Benussi et al., Cell Death & Disease, 2018), (ii) the mTORC1 inhibitor everolimus (Silic-Benussi et al., Redox Biology, 2022), (iii) the calcium antagonist verapamil (Silic-Benussi et al., Antioxidants, 2023), and (iv) the BCL2 inhibitor venetoclax (Urso et al., Signal Transduction and Targeted Therapy, 2025). Building on these findings, we are developing more potent and selective inhibitors of these pathways. Preliminary data indicate that this strategy may also be effective in acute myeloid leukemia (AML), a disease still associated with poor outcomes. | Basic and translational research |
| Sarcoma and bone tumors Research Group (Oncology 1) PI Dr Antonella Brunello | – Clinical trials with innovative drugs – Clinical, strategy studies in collaboration with Sarcoma surgery Unit – Translational studies on prognostic/predictive biomarkers in sarcoma; – Studies on tumor microenvironment , with focus on chondrosarcoma (in collaboration with IDMO) – Registry studies for rare sarcomas, within collaborative groups (EORTC, Italian Sarcoma Group, EURACAN, World Sarcoma Network) | Clinical trials (no profit and profit); observational ambispective studies; translational studies; data collection within registry studies for rare tumors |
| Thoracic cancers (NSCLC, SCLC, TETs, PM) Thoracic Cancers Unit, Oncology 2 (PI Prof Giulia Pasello) | – Innovative drugs clinical development: bispecific ICIs, T-cell engagers, cancer vaccines, ADCs, targeted drugs (NSCLC, SCLC, PM) -Tumor microenvironment dissection, with focus on immune and metabolic biomarkers, and their correlation with clinical outcomes (NSCLC, SCLC; PM) -Investigation of new biomarkers for patient’s outcome stratification and treatment selection (SCLC, PM) -Identification of resistance mechanisms emerging under selective pressure of targeted agents through liquid biopsy -Inflammatory and genomic circulating biomarkers and correlation with efficacy and toxicity of immune checkpoint inhibitors – Real-world and observational investigation of effectiveness and safety of innovative drugs introduced in the clinical practice (ICIs, TKIs) – Radiomics analyses within observational or interventional studies | Profit and no profit interventional clinical trials; investigator’s driven translational prospective studies; observational ambispective studies |
| Colorectal surgery Research Group (PI Boris Franzato) | The research group is focused on translational studies on nutrition and immune system research, quality of life after surgery research, studies on tumor microenvironment, translational studies on prognostic and predictive biomarkers. Key areas: immune response on tumor after immunonutrition, advanced surgical strategies for colorectal surgery, Utility of robotic surgery in quality of life improvement, predictors of anastomotic leak in colorectal surgery development, new technical developments to reduce anastomotic fistula incidence, ERAS program. | Randomized prospective studies, observational retrospective and prospective studies, data collection. |
| Experimental Oncology group (PI Prof Stefano Indraccolo, Dr. Valeria Tosello) | This research group has two main interests. The first project is mainly focused on understanding the metabolic adaptations of tumors to anti-angiogenic therapy and the mechanisms involved in this phenomenon, with the long-term aim to identify new metabolic drugs to improve therapeutic efficacy of angiogenesis inhibitors in cancer. The second project, in collaboration with several clinical units, aims to develop liquid biopsy technologies to predict patient’s response and toxicity of systemic therapies in lung cancer patients. | Translational research |
| Haematologic Neoplasms Genetics and Genomics (PI Dr Edoardo Peroni) | The focus encompasses the molecular characterization of myeloid and lymphoid malignancies, with particular emphasis on myeloproliferative neoplasms (MPN), including myelofibrosis (MF), and acute lymphoblastic leukemia (ALL). Through integrative approaches combining next-generation sequencing, single-cell sequencing, RNA profiling, and spatial multi-omics, the aim is to investigate the genetic, transcriptional, and immunogenetic mechanisms underlying disease evolution, microenvironmental interactions, and therapeutic resistance. | Basic and translational research |
| Hepato-Pancreato-Biliary Surgery Reasearch Group (Unit of Surgical Oncology of Digestive Tract) – PI Dr Mario Gruppo | Biomarkers, molecular profiling and pancreatic tumor microenviroment, with particular interest in inflammatory markers, aberrant myelopoiesis and fibroblast activation protein (in collaboration with IDMO); Translational studies on prognostic/predictive biomarkers in pancreatic cancer. The group collaborates in national and international research networks on pancreatic and periampullary neoplasms and surgical post-pancreatectomy outcomes. | Observational retrospective and prospective studies; translational studies; data collection within registry studies |
| Hereditary Tumors and associated Syndromes (PI Dr Stefania Zovato, Dr Silvia Tognazzo, Dr Alfonso Massimiliano Ferrara) | The research group is involved in the study of people with genetic variants in: -breast, ovarian, prostate and pancreatic cancers -Gastro-intestinal cancers -Endocrine Tumors -Renal cancer -Melanoma -Rare Diseases (VHL syndrome; Li Fraumeni syndrome). Principal aims of the group are: -set precision surveillance strategies and risk reducing proposals for gene carriers depending on peculiar personal genetic risk. -study of innovative therapies for gene carriers | Translational studies; Data collection within Redcap for rare Syndromes |
| Human Tumor Immunology (PI Prof Susanna Mandruzzato) | The research group investigates the dysregulation of myeloid cells in cancer patients, with a particular focus on primary brain tumors such as gliomas and meningiomas. The team studies the immunosuppressive roles of macrophages and circulating myeloid cells, exploring the molecular and metabolic mechanisms that drive their pro-tumor functions. By combining conventional methodologies with multi-omic and advanced imaging approaches, the group characterizes myeloid cell heterogeneity and metabolic adaptations. Ongoing collaborations with neuro-oncology clinical teams also support studies on the expansion and clinical significance of circulating myeloid-derived suppressor cells (MDSCs) in cancer patients. | From basic to translational research |
| Integrated Liquid Biopsy Group (PI Dr Maria Chiara Scaini) | The activities of the Integrated Liquid Biopsy group focus on: Enumeration, phenotypic and genetic characterization of Circulating Tumor Cells (CTCs) and Circulating Melanoma Cells (CMCs); Genetic analyses of circulating tumor DNA (ctDNA) ; Enumeration, phenotypic, and transcriptomic characterization of extracellular vesicles (EVs); The main goal is to apply a multimodal liquid biopsy approach to monitor cancer patients during therapy and to detect early signs of therapeutic resistance before clinical relapse. | Translational research |
| Melanoma/Skin cancers Research Group (PI Dr Jacopo Pigozzo) | The Melanoma/Skin cancers Research Group conducts clinical and translational research focused on melanoma and rare skin cancers, including Merkel cell carcinoma. The group aims to characterize the biological and clinical determinants of response and resistance to immune checkpoint inhibitors and targeted therapies, integrating real-world data with molecular and immunologic analyses. Research activities include observational and translational studies assessing treatment outcomes and resistance mechanisms, as well as the identification of prognostic and predictive biomarkers. Special attention is devoted to rare and aggressive cutaneous malignancies. The group contributes to and coordinates national collaborations aimed at improving diagnostic accuracy, therapeutic strategies, and long-term patient management. | Clinical trials (profit and non-profit); investigator-initiated studies/translational projects. |
| Peritoneal surface malignancies Research Group (Unit of Surgical Oncology of Digestive Tract), PI Dr Antonio Sommariva | The research group is focused on clinical and translational studies for selection and treatment strategies of primary and secondary peritoneal malignancies Activities include: – clinical trials on prognostic and predictive biomarkers to improve clinical practice – preclinical studies on tumor microenvironment and immune profiling for identification of innovative targets and approaches – clinical trials on innovative and mini-invasive locoregional treatments -multicentric studies within collaborative groups (Italian Society of Surgical Oncology, Peritoneal Surface Oncology | Clinical trials; observational retrospective and prospective studies; translational studies; data collection within registry studies for rare peritoneal tumors |
| Radiology and Artificial Intelligence Research Group (PI Dr Francesca Caumo, Dr Gisella Gennaro) | Development and clinical validation of artificial intelligence tools for breast, thoracic imaging; radiomic analysis for prediction and treatment response assessment; integration of imaging biomarkers into personalized diagnostic and therapeutic pathways; evaluation of emerging imaging modalities (contrast-enhanced mammography, MR without helium, low-dose CT); workflow optimization and clinical decision support systems based on AI-driven image interpretation. | Clinical trial, no profit; observational data collection; translational and imaging research; academic studies; multicentric collaborative projects |
| Research group on radiation oncology (group leader Prof Marco Krengli) | The group focuses mainly on the following topics:1) Identification of new biomarkers of radiosensitivity/resistance for patient stratification and personalized radiotherapy treatment; 2) Innovative radiotherapy approaches integrated with other cancer treatments. This topic addresses issues of feasibility, effectiveness and side effects of innovative radiotherapy techniques used in combination or not with other cancer treatment modalities for a wide range of tumors; 3) Personalized radiation therapy approaches in pediatric patients | The group is involved in both translational research funded by grants and also in a series of clinical no- profit and for- profit studies, including investigator initiated ones covering a wide range of tumor types. The group is also very active at international level through participation in EU funded projects |
| Synthetic Immunology (PI Dr Giulia Pasqual) | Research carried out in our lab is focused on the study of cell-cell interactions in the immune system. We are mostly interested in characterising interaction networks relevant for T cell activation and T cell based immunotherapy in the context of cancer. | Basic and translational research |
| Technological optimization (group leader Dr Marta Paiusco) | The main research areas of the groups are:1) Optimization in radiotherapy. In detail:development and clinical implementation of AI-driven adaptive radiotherapy workflows; Exploration of the use of radiomic features extracted from radiotherapy dose distributions (dosiomics) for treatments prognostication; Set-up of prediction model on the basis of imaging biomarkers, multiple therapeutic intervention and dose distribution characteristics in neurological radiotherapy; Plan-specific Evaluation of Complexity Indicators For Improved Quality Assurance(SPECIFIQA); Real-time Lesion Tracking in Radiotherapy; Implementation and Development of Spatially Fractionated Radiotherapy (SFRT). 2) Dose optimization in diagnostics. Precisely: SONORA project aims to evaluate, measure and validate the fetal dose during radiological examinations (CT, RX, XA); Assessment and improvement of staff) and patient dosimetry.3) 3D Printing in Radiation Oncology | translational study |
| Thyroid Tumors research group (PI Dr Stefania Zovato, Dr Gino Crivellari, Dr Sara Watutantrige) | The research group is involved in the study of patients with Thyroid cancer, in particular: -Differentated cancer -Medullary cancer -Anaplastic cancer Principal aims are: -study of molecular biomarkers -efficacy of target therapy -Genetic assessment and efficacy to treatment | Clinical trials (no profit and profit); observational retrospective and prospective studies Data collection |
| Translational Research Group (PI Dr Marina Coppola) | The research group focuses on precision medicine, integrating clinical pharmacology (pharmacokinetics and pharmacodynamics), pharmacogenetics, and the optimization of complex therapies in polytreated patients, with direct translation into clinical practice. The aim is to improve oncological treatment optimization and early toxicity management through proximity-based care models, digital health tools for remote monitoring, and a virtual multidisciplinary clinic. The group also conducts Health Technology Assessment (HTA), drug utilization, and pharmacoeconomic studies on novel therapies, medical devices, and innovative technologies. Research also includes chemical-physical e microbiological stability and studies of compounded magistral preparations, and on radiopharmaceuticals generating real-world evidence to support sustainable, appropriate, and equitable healthcare.The group includes numerous intra- and extra-institutional collaborations (with healthcare companies, IRCCS institutes, universities, and scientific societies ) to ensure multidisciplinary and high expertise in each project. | Non-profit and profit clinical trials (including interventional pharmacological and non-pharmacological studies, as well as investigations involving medical devices), observational data collection, translational and laboratory research, and academic studies in the field of translational research. |
| Tumor Immunology Laboratory (PI Prof Antonio Rosato) | The research group integrates cutting-edge technologies and multidisciplinary expertise to advance cancer immunotherapy from preclinical development to clinical translation. The group specializes in the engineering of antigen-specific targeting molecules and next-generation cell therapies, including CAR-T, CAR-NK, and CIK cells, supported by state-of-the-art in vitro, in vivo, and single-cell omics platforms. With strong capabilities in tumor microenvironment profiling, theranostic agent development, and cancer vaccine innovation, the lab offers a fully integrated translational pipeline. Its established GMP and clinical trial collaborations enable rapid transition from experimental design to first-in-human applications. | From basic to translational research |
| Tumor microenvironment Lab (PI Prof Ilaria Marigo) | Our lab investigates the mechanisms exploited by tumors to evade the immune response and to re-educate the immune infiltrate in its favor. Main research areas: 1. Profiling of tumor-associated macrophages in solid tumors and metastasis: We are profiling the immune microenvironment using multi-parametric flow cytometry and spatial multiomics approaches to better understand the mechanisms underlying immune evasion that lead to tumor progression and resistance to therapy in sarcomas and peritoneal metastases of colorectal cancer. We analyze the tumor microenvironment before and after treatment, and at different progression stages of the tumors. 2. Developing new strategies to overcome immunotherapy resistance: We are refining existing therapeutic approaches, such as adoptive cell therapy and immune checkpoint inhibitors (ICIs) by specifically targeting immunosuppressive macrophages. Concurrently, we are developing novel methods using nanotechnology approaches to improve drug or mRNA delivery to modulate the immnosuppressive populations administrated in the section cavity cranium of glioblastoma models. These strategies are combined with radiotherapy and ICI treatments. 3. Developing a cross-species nanoplatform for imaging and therapeutic modulation of the premetastatic niche: We are developing a novel, aptamer-based nanoplatform engineered to specifically target and bind tumor-derived extracellular vesicles (tEVs). By leveraging this specific binding mechanism, the platform will be used to unveil the functional role of tEVs in dictating metastatic site determination. This tool will enable the precocious in vivo visualization of premetastatic niche (PMN) formation, thereby facilitating in-depth study of the immunological processes underlying its development. Furthermore, the nanoplatform will be designed to function as a targeted delivery system for therapeutic agents, allowing for the modulation of the niche itself and subsequent prevention of metastatic disease. | From basic to translational research |
| Tumor molecular biomarkers and viral oncology (PI Dr Maria Raffaella Petrara, Dr Silvia Giunco) | The research group is focused on two aspects of tumorigenesis: 1. Cellular replicative potential: telomere and telomerase. We study the cellular replicative potential by analyzing telomeres and telomerase, key elements in tumor immortalization. Telomere shortening reflects senescence, biological aging and promotes genomic instability, while TERT reactivation supports proliferation and promotes tumor aggressiveness and progression. Through molecular assays and clinical studies, we evaluate telomeres, TERT, and mutations in its promoter as prognostic biomarkers of cancer onset and progression, as well as potential therapeutic targets. 2. Multifaceted aging profile as a predictive/prognostic biomarker of cancer onset. We aim to evaluate the predictive and prognostic significance of a comprehensive aging signature by integrating multiple biomarkers. This includes established biological markers, such as thymic output, telomere length, epigenetic age, mitochondrial DNA copy number, immunophenotypic features (activated, senescent, exhausted and regulatory T and B cells), circulating senescent and inflammatory biomarkers (SASPs), muscle wasting and denervation biomarkers (NCAM1 and CAF), and new aging markers, such as TERRA and ROS levels, in different cohorts of 1- patients with solid and hematologic malignancies and 2- individuals at higher risk of accelerated aging and aging-associated cancers, due to immunosuppression for transplantation or HIV. | Basic and translational research |
| Upper GI Group (Oncologic Surgery) PI Dr Pierluigi Pilati | The research group is focused on treatment strategies for upper GI malignancies. Activities include: -clinical, translational, observational studies on prognostic value of liquid biopsy, cell free DNA and platelets The group collaborates in multidisciplinary and national research networks, supporting the advancements into upper GI care | Clinical trials (no profit); observational studies; data collection within registry studies for upper GI tumors; narrative review |
ONCO-HAEMATOLOGICAL RESEARCH TEAM
ONCOLOGY 1 UNIT
- New therapeutic approach in lymphoma
- Diffuse large B cell lymphoma in elderly patients
- Molecular prognostic factors in Diffuse Large B cell lymphoma
NETWORK CLINICAL RESEARCH GROUP
ONCOLOGY 2 UNIT
- Evaluation of the impact of the diagnostic-therapeutic pathways in oncology
- Regional and National collection of real world data on activity, efficacy, safety and budget impact of innovative anticancer drugs
- Regional and National prospective clinical studies
- Administrative health data extraction on diagnosis and treatment of breast and lung cancer